Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Tathmini ya Kawaida ya Kipimo cha Kuchunguza× | Tathmini ya Kipimo cha Kuchuja× | |
|---|---|---|
| Nyanja | Epidemiolojia | Epidemiolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 1980s–2000s (STARD 2003, updated 2015) | 1968 (Wilson-Jungner principles); statistical framework developed 1970s–2000s |
| Mwanzilishi≠ | Formalized through diagnostic accuracy methodology (Sackett, Haynes, Tugwell; STARD initiative) | Wilson & Jungner (WHO criteria, 1968); foundational work by Pepe, Altman, and others in statistical test evaluation |
| Aina≠ | Prospective observational study design | Observational diagnostic / epidemiological evaluation design |
| Chanzo asilia≠ | Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., et al. (2015). STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. BMJ, 351, h5527. DOI ↗ | Wilson, J. M. G., & Jungner, G. (1968). Principles and Practice of Screening for Disease. World Health Organization. Public Health Papers No. 34. link ↗ |
| Majina mbadala | prospective diagnostic accuracy study, prospective test performance study, forward-looking screening validation, prospective DTA study | screening study, screening performance evaluation, screening accuracy assessment, STE |
| Zinazohusiana | 6 | 6 |
| Muhtasari≠ | A prospective screening test evaluation enrolls participants before the outcome is known, applies the screening test and the reference standard in temporal sequence, and measures how accurately the test identifies individuals with or without the target condition. This forward-looking design minimizes workup bias and spectrum bias, producing estimates of sensitivity, specificity, and predictive values that are more generalizable to real clinical or public-health screening contexts than retrospective alternatives. | Screening test evaluation is a systematic epidemiological approach for assessing whether a test or program can accurately and cost-effectively identify individuals with a condition before symptoms appear. It quantifies diagnostic performance metrics — sensitivity, specificity, predictive values, and the ROC curve — and evaluates whether a screening program meets established public health criteria for adoption and harm-benefit balance. |
| ScholarGateSeti ya data ↗ |
|
|